Randomized clinical trial

Randomized clinical trial of topical tranexamic acid after reduction mammoplasty

K. Ausen1, R. Fossmark2,5, O. Spigset3,6 and H. Pleym4,7

Departments of 1Plastic and Reconstructive Surgery, 2Internal Medicine and 3Clinical Pharmacology, and 4Clinic of Anaesthesia and Intensive Care, St Olav’s University Hospital, and Departments of 5Cancer Research and Molecular Medicine, 6Laboratory Medicine, Children’s and Women’s Health, and 7Circulation and Medical Imaging, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway

Correspondence to: Dr K. Ausen, Department of Plastic and Reconstructive Surgery, St Olav’s University Hospital, PO Box 3250 Sluppen, N-7006 Trondheim, Norway (e-mail: kjerstiausen@gmail.com)

Background: The antifibrinolytic drug tranexamic acid is currently being rediscovered for both trauma and major surgery. Intravenous administration reduces the need for blood transfusion and blood loss by about one-third, but routine administration in surgery is not yet advocated owing to concerns regarding thromboembolic events. The aim of this study was to investigate whether topical application of tranexamic acid to a wound surface reduces postoperative bleeding.

Methods: This was a randomized double-blind placebo-controlled trial on 30 consecutive women undergoing bilateral reduction mammoplasty. On one side the wound surfaces were moistened with 25 mg/ml tranexamic acid before closure, and placebo (saline) was used on the other side. Drain fluid production was measured for 24 h after surgery, and pain was measured after 3 and 24 h. Postoperative complications including infection, seroma, rebleeding and suture reactions were recorded.

Results: Topical application of tranexamic acid to the wound surface after reduction mammoplasty reduced drain fluid production by 39 per cent (median 12.5 (range 0–44) versus 20.5 (0–100) ml; P = 0.038). Adverse effects were not observed. There were no significant differences in postoperative pain scores or complications.

Conclusion: Topical application of dilute tranexamic acid reduced bleeding in this model. The study adds to the evidence that this simple procedure may reduce wound bleeding after surgery. Registration number: NCT01964781 (http://www.clinicaltrials.gov).

Introduction

When fibrinolysis exceeds coagulation, unwanted surgical bleeding may occur despite adequate haemostasis. Tranexamic acid is the most commonly used medication to prevent fibrinolysis. It acts by blocking the lysine-binding sites on plasminogen, thereby preventing the activation of plasminogen to plasmin1. Tranexamic acid can be administered orally or intravenously, but topical use is being reported increasingly.

Intravenous administration of tranexamic acid during major surgery has been shown to reduce the need for blood transfusion by 32–37 per cent, as well as measurable postoperative bleeding by 34 per cent2,3. The dose has varied considerably4, from 1 to 20 g administered intravenously over 20 min to 12 h. Suggested single intravenous doses are 1–2 g5,6. The minimal effective plasma concentration is unknown5,7–9. Safety concerns have included thrombosis, renal impairment, and increased risk of seizures associated with high doses (above 2 g)10. Definitive causal relationships have not been established11,12 but, as adverse effects may be dose-related, and doses above 1–2 g seem to provide no added benefit, high-dose intravenous administration is discouraged. Because of uncertainty about the effect of tranexamic acid, particularly on vascular occlusive events, it is still not recommended for routine use during most surgical procedures13.

Topical application of tranexamic acid provides a high drug concentration at the site of the wound and a low systemic concentration14,15. Studies from cardiac and orthopaedic surgery have shown an equal or superior effect of topical compared with intravenous tranexamic acid on both bleeding and transfusion requirement16–20. Topical treatment is cost-effective21, and adverse effects or drug interactions have not been reported.
In previous studies, topical tranexamic acid was instilled mainly as a bolus into confined spaces such as a joint, the mediastinum or the pericardium, or applied to accessible wounds using soaked gauze. A few studies have described simple moistening of a wound surface. Whereas most topical haemostatic agents can cover only a small surface area, tranexamic acid diluted in saline can moisten large areas, such as after massive weight loss surgery, or in patients with burns.

The aim of this study was to investigate whether moistening a wound surface with tranexamic acid reduces bleeding. This hypothesis was tested in a randomized double-blind placebo-controlled study of women undergoing bilateral reduction mammoplasty, where effects of intervention on one breast can be evaluated by comparison with the other.

Methods

Consecutive women above 18 years of age undergoing bilateral reduction mammoplasty at the Department of Plastic Surgery, St Olav’s University Hospital, Trondheim, Norway, were eligible for inclusion in the study. Exclusion criteria were: a history of any thromboembolic disease, pregnancy or severe co-morbidity (American Society of Anaesthesiologists (ASA) fitness grade III or IV). Women using platelet-inhibiting drugs or anticoagulants were not excluded automatically. Written informed consent was obtained from all participants before inclusion.

Randomization and masking

The women were randomized to receive topical tranexamic acid to one breast and placebo to the other after reduction mammoplasty. Randomization was performed electronically by the Unit of Applied Clinical Research at the Norwegian University of Science and Technology (NTNU-Trondheim) (http://www.ntnu.edu/dml/akf/randomisering). Sealed envelopes were prepared stating whether the right or left side was to receive tranexamic acid according to the randomization. All personnel involved in surgery and postoperative follow-up were blinded to the randomization. The randomization code was kept at the Unit of Applied Clinical Research and was not broken until 4 weeks after the last patient had been enrolled.

Intervention

As the specific mode of topical application of tranexamic acid has not been published previously, the concentration of tranexamic acid needed to achieve an antifibrinolytic effect was unknown. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a fairly large wound surface: 20 ml moistens at least 1500 cm². On the morning of surgery, a nurse not involved in the procedure prepared two identical plastic bottles of 20 ml saline (0.9 per cent sodium chloride), marking them right and left. She then opened the sealed envelope with the patient’s project identification number. On the side stated in the envelope, 5 ml saline was extracted from the bottle and replaced with 5 ml of 100 mg/ml tranexamic acid. The prepared solution thus contained 20 ml of 25 mg/ml tranexamic acid. The other bottle (placebo) received only an identical needle puncture. The solutions were colourless, so the two bottles looked identical apart from their right and left markings. The bottles were then brought to the operating theatre.

Two surgeons performed the operation, operating on one breast each. Equal amounts of local anaesthetic were injected into the breasts at the end of surgery in accordance with the hospital’s prevailing routine for reduction mammoplasty (20 ml of 1 mg/ml lidocaine with 5 μg/ml adrenaline and 20 ml of 2.5 mg/ml bupivacaine (AstraZeneca, London, UK) diluted in 120 ml saline for each breast). After resecting the breast tissue, the surgeons switched sides to evaluate/improve haemostasis, thus securing homogeneous wounds and equivalent operating times. The weight of resected tissue was recorded. The contents of the appropriate bottles containing tranexamic acid or placebo were smeared on to the wound surfaces before closure, taking care not to use moist swabs or gloves on the opposite side. Vacuum drains (Exudrain™ FG 14; AstraZeneca) were placed symmetrically, the wounds were closed with standard subcutaneous and intracutaneous suturing, and standard compression garments were fitted. The patients received oral analgesics after surgery, but no routine thromboprophylaxis; this is standard practice after reduction mammoplasty at this hospital.

Follow-up

All women were interviewed by a nurse 3 and 24 h after surgery. Drain fluid volume was recorded 24 h after surgery, and drains were removed when production was below 40 ml per 24 h, according to hospital routine. Haematoma needing reoperation within 24 h was registered. All women also had an outpatient appointment with one of the surgeons 3 months later. The women were encouraged to contact the hospital if any complications occurred.

Outcomes

The primary outcome was drain fluid production in the first 24 h after surgery. The drain fluid was not analysed...
Results

Of 36 women eligible for inclusion, six declined participation and 30 women were therefore enrolled. No patient withdrew after enrolment. Two were, however, excluded just before surgery (1 had a complete mastectomy instead of reduction mammoplasty; the other was recognized to have had a previous myocardial infarction and was considered ASA grade III). Tranexamic acid and placebo were not administered to these patients. Twenty-eight women remained eligible for final analyses (Fig. 1); their median age was 45 (18–67) years. None of the women used platelet inhibitors or anticoagulants. Mean resected tissue weight per breast was 415 (162) g.

Drain production was 39 per cent lower in breasts treated with tranexamic acid compared with breasts treated with placebo: median 12.5 (0–44) versus 20.5 (0–100) ml respectively ($P = 0.038$) (Table S1 and Fig. S1a, supporting information). To adjust for possible differences in wound surface areas owing to unequal size of the two breasts, a separate analysis was done with drain volume adjusted for resected weight. This analysis showed 42 per cent lower drain fluid production in breasts treated with tranexamic acid: median 12.9 (0–47) versus 22.0 (0–100) ml respectively ($P = 0.017$) (Table S1 and Fig. S1b, supporting information). Only one of 28 breasts treated with tranexamic acid produced 40 ml or more of fluid (44 ml), compared
with nine of 28 placebo-treated breasts \((P = 0.016)\). Two of these in the placebo group required reoperation and evacuation of haematoma.

Pain scores were similar in breasts treated with tranexamic acid or placebo on the day of surgery (median 2.5 (0–6) versus 2.0 (0–6); \(P = 0.179\)) and after 24 h (2.0 (0–6) versus 2.0 (0–5) respectively; \(P = 0.428\)).

No adverse effects were recorded after topical tranexamic acid. Five patients had a wound infection treated with antibiotics or outpatient wound drainage within 6 weeks of surgery. Another six women had a superficial inflammatory reaction related to the sutures. These had no relation to treatment with tranexamic acid or placebo. One woman had bilateral wound seromas which were evacuated.

**Discussion**

The present study showed that topical application of tranexamic acid significantly reduced wound drainage after reduction mammoplasty.

The main strength of the study is the model. Surface wounds can be diverse (burns, massive weight loss surgery), and it is challenging to design a study with equivalent wounds. Women undergoing bilateral reduction mammoplasty provide two almost identical wounds in an ordinary clinical setting. A small study can thus provide adequate statistical power.

The study, however, has several weaknesses. It was conducted using a surgical procedure that is not usually associated with major bleeding. Drain volumes, not blood loss, were measured; drain fluids consist of both blood and transudates, with a transition over time to more serous drain fluid. The breasts had also been injected with local anaesthetic containing adrenaline (epinephrine), but with equal volumes in each breast. The constituents of the drain fluids were not analysed, but registration took place during the first 24 h when the drainage is mostly blood. Whether topical tranexamic acid can influence transudate production or even seroma formation through its inhibition of fibrinolysis remains unknown.

The wounds after reduction mammoplasty are not completely identical, particularly when two surgeons operate, one side each. To correct for this, the surgeons undertook haemostasis on the contralateral side, and a separate analysis of drain volumes was done with adjustment for resected tissue weight.

Serum concentrations of tranexamic acid were not measured. Systemic absorption of topical tranexamic acid could in theory affect bleeding from the contralateral placebo wound. *In vitro*, a minimum concentration of 5–10 μg/ml is needed to inhibit fibrinolysis\(^{1,7}\). Studies in orthopaedic and cardiac surgery have found a negligible systemic concentration from application of boluses of tranexamic acid in confined spaces\(^{14,15}\). The tranexamic acid dose in the present study was 20 ml of 25 mg/ml, a total of 500 mg; this method should give a very low systemic concentration\(^{14,15}\).

The overall reduction in drain fluid production of about 40 per cent after topical administration of tranexamic acid here accords with previously published studies\(^{3,16–20}\), which consistently reported a reduction in transfusion need and measurable bleeding of between 30 and 40 per cent after both intravenous and topical tranexamic acid administration. There is little information on the concentration of tranexamic acid needed for topical effect. Instillation of a bolus of 1–3 g tranexamic acid diluted in 100 ml saline (concentration 10–30 mg/ml) has been studied in patients undergoing cardiac\(^{15,16}\) and orthopaedic\(^{17}\) surgery, whereas epistaxis has been treated with sponges moistened with undiluted tranexamic acid for intravenous use \((100 \text{ mg/ml})^{31}\). This present study opted for a high concentration of 25 mg/ml, but still dilute enough to provide a volume sufficient to moisten large surface areas. There are few published studies where the mode of application was comparable to the moistening used in this study. A mouthwash containing 4–8 mg/ml tranexamic acid was effective after dental extraction\(^{28}\), whereas Hinder and Tschopp\(^{26}\) found no significant effect of gargling 1–7 mg/ml tranexamic acid solution after tonsillectomy. Athanasiadis and colleagues\(^{27}\) reported a significant effect after spraying the wound surfaces with tranexamic acid in endoscopic sinus surgery. The optimal concentration remains unknown.

The use of drains after reduction mammoplasty has little scientific evidence\(^{35}\) but is nevertheless common. At the time of study, the departmental routine was to use drains until fluid production was below 40 ml per 24 h. The present study suggests that topical tranexamic acid reduces drain fluid production after reduction mammoplasty to below this cut-off value in almost all patients, and may obviate the need for a drain.

There were two postoperative bleeds in the study, both in untreated breasts. The study was not powered to evaluate whether topical tranexamic acid could prevent postoperative haematoma. Ngaage and Bland\(^{9}\) reported that intravenous tranexamic acid reduced the risk of reoperation by 48 per cent after coronary surgery, and a significant reduction in rebleeding after tonsillectomy was described for the lysine analogue aminocaproic acid\(^{16}\). Few studies on tranexamic acid have reported rebleeding as an outcome measure\(^{3,37}\).

Tranexamic acid is inexpensive. Its cost-effectiveness has been thoroughly documented in orthopaedic surgery\(^{21}\). Even after operations where bleeding is less common,
topical application of tranexamic acid may reduce the need for drains and outpatient visits. This simple method has potential for widespread application after surgery.

Acknowledgements

The authors thank K. Fonstad for including all the patients in this study, I. Spets for randomization and preparation of drugs, and E. Saetnan, K. Sneve, C. Gonzales, H. Nordgaard and K. Gullestad for their contribution to the study. This research was conducted using funding from the Department of Plastic and Reconstructive Surgery at St Olav’s University Hospital.

Disclosure: The authors declare no conflict of interest.

References

1 Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57: 1005–1032.
2 Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg 2013; 100: 1271–1279.
3 Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012; 344: e3054.
4 Ngaage DL, Bland JM. Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies. Eur J Cardiothorac Surg 2010; 37: 1375–1383.
5 Horror JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose–response relationship of tranexamic acid. Anesthesiology 1995; 82: 383–392.
6 Poeran J, Rasul R, Dunninger T, Mazumdar M, Opperer M et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ 2014; 349: g4829.
7 Yee BE, Wissler RN, Zanghi CN, Feng C, Eaton MP. The effective concentration of tranexamic acid for inhibition of fibrinolysis in neonatal plasma in vitro. Anesth Analg 2013; 117: 767–772.
8 Andersson L, Eriksson O, Hedlund PO, Kjellman H, Lindqvist B. Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urol Res 1978; 6: 83–88.
9 Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002; 97: 390–399.
10 Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010; 110: 350–353.
11 Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011; (3)CD001886.
12 Koster A, Schirmer U. Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anaesthesiol 2011; 24: 92–97.
13 Ker K, Roberts I. Tranexamic acid for surgical bleeding. BMJ 2014; 349: g4934.
14 Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am 2010; 92: 2503–2513.
15 De Bonis M, Cavaliere F, Alessandri F, Lapenna E, Santarelli F, Moscato U et al. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg 2000; 119: 575–580.
16 Ipepa HJ, Tanzi MG. Use of topical tranexamic acid or aminocaproic acid to prevent bleeding after major surgical procedures. Ann Pharmacother 2012; 46: 97–107.
17 Gomez-Barrena E, Ortega-Andreu M, Padilla-Eguiluz NG, Pérez-Chrzanowska H, Figueredo-Zalve R. Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am 2014; 96: 1937–1944.
18 Wind TC, Barfield WR, Moskal JT. The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty. J Arthroplasty 2013; 28: 1080–1083.
19 Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials. Knee 2014; 21: 987–993.
20 Alshryda S, Sukeik M, Sarda P, Blenkinsopp J, Haddad FS, Mason JM. A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Joint J 2014; 96-b: 1005–1015.
21 Tuttle JR, Ritterman SA, Cassidy DB, Anazonwu WA, Froehlich JA, Rubin LE. Cost benefit analysis of topical tranexamic acid in primary total hip and knee arthroplasty. J Arthroplasty 2014; 29: 1512–1515.
22 Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth 2009; 56: 202–212.
23 Zahed R, Moharamzadeh P, Alizadehkarasi S, Ghasemi A, Saeedi M. A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. Am J Emerg Med 2013; 31: 1389–1392.
24 Sarris I, Arafa A, Konaris L, Kadir RA. Topical use of tranexamic acid to control perioperative local bleeding in
gynaecology patients with clotting disorders: two cases. *Haemophilia* 2007; 13: 115–116.
25 Tang YM, Chapman TW, Brooks P. Use of tranexamic acid to reduce bleeding in burns surgery. *J Plast Reconstr Aesthet Surg* 2012; 65: 684–686.
26 Hinder D, Tschopp K. [Topical application of tranexamic acid to prevent post-tonsillectomy haemorrhage.] *Laryngorhinootologie* 2015; 94: 86–90.
27 Athanasiadis T, Beule AG, Wormald PJ. Effects of topical antifibrinolytics in endoscopic sinus surgery: a pilot randomized controlled trial. *Ann J Rhinol* 2007; 21: 737–742.
28 Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. *Ann Pharmacother* 2006; 40: 2205–2210.
29 Barnard J, Millner R. A review of topical hemostatic agents for use in cardiac surgery. *Ann Thorac Surg* 2009; 88: 1377–1383.
30 Sterling JP, Heimbach DM. Hemostasis in burn surgery – a review. *Burns* 2011; 37: 559–565.
31 Walsh K, Nikkhah D, Dheansa B. What is the evidence for tranexamic acid in burns? *Burns* 2014; 40: 1055–1057.
32 Kjersti A. 20 ml Fluid on AquaDoodle Canvas. https://youtu.be/10AkwMQSEIs [accessed 1 March 2015].
33 Paired t-test. http://www.biomath.info/power/prt.htm [accessed 2 January 2012].
34 Lehmann EL. Comparing two treatments of attributes in a population model. In: *Nonparametrics: Statistical Methods Based on Ranks*, Lehmann EL (ed). Springer: New York, 1998; 76–81.
35 Stojkovic CA, Smeulders MJ, Van der Horst CM, Khan SM. Wound drainage after plastic and reconstructive surgery of the breast. *Cochrane Database Syst Rev* 2013; (3):CD007258.
36 Overbosch HC, Hart HC. Local application of epsilon-aminocaproic acid (E.A.C.A.) in the prevention of haemorrhage after tonsillectomy. *J Laryngol Otol* 1970; 84: 905–908.
37 Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. *Cochrane Database Syst Rev* 2013; (7):CD010562.

**Supporting information**

Additional supporting information may be found in the online version of this article:

**Table S1** Drain fluid production measured 24 h after surgery in patients undergoing bilateral reduction mammoplasty (Word document)

**Fig. S1** a Drain fluid production measured 24 h after surgery and b drain fluid volume adjusted for resected tissue weight (Word document)

**Editor’s comments**

This paper, and the FIBER Study preceding it (*Br J Surg* 2015; 102: 1338–1347), both explore pharmacological means to reduce perioperative bleeding. *BJS* does not normally publish cardiac papers, but makes an exception because of the high quality of the study. Although essentially a negative trial, the FIBER Study has valuable clinical implications, and is a reminder of the importance of publishing such trials. This study by Ausen et al. also has a favoured within-patient randomization design using an established agent (tranexamic acid) topically. This study has a positive result (median reduction of 8 ml in drain fluid) but the clinical relevance remains unclear, as does whether it would stand up to a formal cost-benefit analysis. Minimizing perioperative bleeding is fundamental, and the methods used in both these RCTs have relevance in other specialties and procedures. Only by conducting high-quality research can the role of pharmacological agents be clarified.

J. J. Earnshaw
Joint Chief Editor, *BJS*